Loris De Cecco
AREA Science Park
GeneCancerInternal medicinePathologyOncologymicroRNAGene expressionTranscriptomeGene expression profilingMicroarrayImmunologyHead and neck cancerHead and neck squamous-cell carcinomaOvarian cancerCancer researchBreast cancerGeneticsBioinformaticsMedicineBiologyImmune system
120Publications
23H-index
2,281Citations
Publications 122
Newest
#1Darawan Rinchai (Qatar Airways)H-Index: 16
#2Elena Verzoni (University of Milan)H-Index: 20
Last. Luca LalliH-Index: 2
view all 0 authors...
BACKGROUND The combination of immune checkpoint blockade (ICB) with standard therapies is becoming a common approach for overcoming resistance to cancer immunotherapy in most human malignancies including metastatic renal cell carcinoma (mRCC). In this regard, insights into the immunomodulatory properties of antiangiogenic agents may help designing multidrug schedules based on specific immune synergisms. METHODS We used orthogonal transcriptomic and phenotyping platforms combined with functional ...
Source
BRAFV600E is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop drug resistance. The mechanisms of BRAF inhibitors response are still poorly understood in a thyroid cancer (TC) context. In this study, we investigated in BRAFV600E mutated TC cell lines the effects of ...
Source
#1Cristina Gurizzan (University of Brescia)H-Index: 1
#2Luigi Lorini (University of Brescia)H-Index: 2
Last. Paolo Bossi (University of Brescia)H-Index: 39
view all 18 authors...
Background Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD and may therefore identify patients carrying higher risk. To date, clinical management of OPMD is limited to surgical excision and clinical surveillance, which however do not fully prevent oral cancer de...
Source
#1Sabina SangalettiH-Index: 27
#2Laura BottiH-Index: 8
Last. Mario P. ColomboH-Index: 101
view all 12 authors...
Summary The secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein with unexpected immunosuppressive function in myeloid cells. We investigated the role of SPARC in autoimmunity using the pristane–induced model of lupus that, in mice, mimics human SLE. Sparc-/- mice developed earlier and more severe renal disease, multi-organs parenchymal damage and arthritis than the WT counterpart. Sparc+/- heterozygous mice showed an intermediate phenotype suggesting Sparc gene-dosage...
Source
#2Paola OstanoH-Index: 19
Last. Giovanna ChiorinoH-Index: 37
view all 21 authors...
Oropharynx squamous cell carcinoma (OPSCC) is a subtype of head and neck squamous cell carcinoma (HNSCC) arising from the base of the tongue, lingual tonsils, tonsils, oropharynx or pharynx. The majority of HPV-positive OPSCCs has a good prognosis, but a fraction of them has a poor prognosis, similar to HPV-negative OPSCCs. An in-depth understanding of the molecular mechanisms underlying OPSCC is mandatory for the identification of novel prognostic biomarkers and/or novel therapeutic targets. 14...
Source
#1Loris De CeccoH-Index: 23
#2Marina BagnoliH-Index: 23
Last. Delia MezzanzanicaH-Index: 35
view all 5 authors...
Epithelial ovarian cancer (EOC) remains the second most common cause of gynecological cancer deaths. To improve patients' outcomes, we still need reliable biomarkers of early relapse, of which external independent validation is a crucial process. Our previously established prognostic signature, MiROvaR, including 35 microRNAs (miRNA) able to stratify EOC patients for their risk of relapse, was challenged on a new independent cohort of 197 EOC patients included in the Pelvic Mass Study whose miRN...
Source
Background Rhabdomyosarcoma (RMS), the most frequent soft-tissue sarcoma in childhood, shows extensive heterogeneity in histology, site and age of onset, clinical course, and prognosis. Adolescents and young adults (AYA) with RMS form a subgroup of patients whose survival lacks behind that of children while diagnosed with histologically similar tumors. Procedures A 67-gene prognostic signature related to chromosome integrity, mitotic control, and genome complexity in sarcomas (CINSARC) is consid...
Source
#2Arianna MicaliH-Index: 1
Last. Mariangela FiginiH-Index: 26
view all 11 authors...
Since the beginning of the COVID-19 outbreak, Cancer Centers adopted specific procedures both to protect patients and to monitor the possible spread of SARS-CoV-2 among healthcare personnel (HCP). In April 2020 at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, one of the three oncologic hubs in Lombardy where the Health Regional Authorities referred all the cancer patients of the region, we implemented a prospective longitudinal study aimed at monitoring the serological response to SARS...
Source
Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling. Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed to...
Source
#1Martina Di ModicaH-Index: 6
#2Giorgio GargariH-Index: 11
Last. Elda TagliabueH-Index: 67
view all 17 authors...
Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of the gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer (BC) and in 24 patients with primary HER2-positive BC undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or ...
2 CitationsSource